Selective activation of individual subtypes of muscarinic receptors is a promising way to safely alleviate a wide range of pathological conditions in the central nervous system and the periphery as well. The flexible G-protein interface of muscarinic receptors allows them to interact with several G-proteins with various efficacy, potency, and kinetics. Agonists biased to the particular G-protein mediated pathway may result in selectivity among muscarinic subtypes and, due to the non-uniform expression of individual G-protein alpha subunits, possibly achieve tissue specificity. Here, we demonstrate that novel tetrahydropyridine-based agonists exert specific signalling profiles in coupling with individual G-protein α subunits. These signalling profiles profoundly differ from the reference agonist carbachol. Moreover, coupling with individual Gα induced by these novel agonists varies among subtypes of muscarinic receptors which may lead to subtype selectivity. Thus, the novel tetrahydropyridine-based agonist can contribute to the elucidation of the mechanism of pathway-specific activation of muscarinic receptors and serve as a starting point for the development of desired selective muscarinic agonists.

• MeSH
• agonisté muskarinových receptorů * farmakologie   MeSH
• CHO buňky MeSH
• Cricetulus MeSH
• karbachol farmakologie   MeSH
• lidé MeSH
• proteiny vázající GTP - alfa-podjednotky metabolismus   genetika   MeSH
• proteiny vázající GTP metabolismus   MeSH
• pyridiny farmakologie   MeSH
• receptory muskarinové * metabolismus   MeSH
• signální transdukce účinky léků   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• agonisté muskarinových receptorů * MeSH
• karbachol MeSH
• proteiny vázající GTP - alfa-podjednotky MeSH
• proteiny vázající GTP MeSH
• pyridiny MeSH
• receptory muskarinové * MeSH

At present, Alzheimer's disease (AD) and related dementias cannot be cured. Therefore, scientists all over the world are trying to find a new approach to prolong an active life of patients with initial dementia. Both pharmacological and non-pharmacological pathways are investigated to improve the key symptom of the disease, memory loss. In this respect, influencing the neuromodulator acetylcholine via muscarinic receptors, such as cevimeline, might be one of the therapeutic alternatives. The purpose of this study is to explore the potential of cevimeline on the cognitive functions of AD patients. The methodology is based on a systematic literature review of available studies found in Web of Science, PubMed, Springer, and Scopus on the research topic. The findings indicate that cevimeline has shown an improvement in experimentally induced cognitive deficits in animal models. Furthermore, it has demonstrated to positively influence tau pathology and reduce the levels of amyloid-β (Aβ) peptide in the cerebral spinal fluid of Alzheimer's patients. Although this drug has not been approved by the FDA for its use among AD patients and there is a lack of clinical studies confirming and extending this finding, cevimeline might represent a breakthrough in the treatment of AD.

• Klíčová slova
• AF102B, Alzheimer disease, SNI2011, cevimeline, cholinergic agonist, cognition, evoxac, memory, muscarinic receptors, neurodegeneration,
• MeSH
• agonisté muskarinových receptorů farmakologie   MeSH
• chinuklidiny farmakologie   MeSH
• kognitivní poruchy farmakoterapie   MeSH
• léčivé přípravky aplikace a dávkování   MeSH
• lidé MeSH
• neurodegenerativní nemoci farmakoterapie   MeSH
• neurofarmakologie * MeSH
• thiofeny farmakologie   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• agonisté muskarinových receptorů MeSH
• cevimeline MeSH Prohlížeč
• chinuklidiny MeSH
• léčivé přípravky MeSH
• thiofeny MeSH